{"id":55100,"date":"2023-03-22T19:05:35","date_gmt":"2023-03-22T18:05:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/"},"modified":"2023-03-22T19:05:35","modified_gmt":"2023-03-22T18:05:35","slug":"poxel-will-report-its-2022-full-year-results-on-march-23-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/","title":{"rendered":"Poxel will Report its 2022 Full Year Results on March 23, 2023"},"content":{"rendered":"<div>\n<p>LYON, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230322005650\/en\/729490\/5\/POXEL_LOGO_Q.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230322005650\/en\/729490\/21\/POXEL_LOGO_Q.jpg\"><\/a><\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxel.com%2F&amp;esheet=53366212&amp;newsitemid=20230322005650&amp;lan=en-US&amp;anchor=POXEL+SA&amp;index=1&amp;md5=83884e370c8189615963882b5a6177f7\" rel=\"nofollow noopener\" shape=\"rect\">POXEL SA<\/a> (Euronext: POXEL &#8211; FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced it will report its 2022 Full year results on March 23, 2023, before market opening.\n<\/p>\n<p>\nThe management team will host webcast conference calls on<b> March 23, 2023<\/b> at:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n1:00 pm CET, Paris time (8:00 am ET) in French and\n<\/li>\n<li>\n<b>9:45 am ET, New York time<\/b> (2:45 pm CET) in <b>English<\/b>.\n<\/li>\n<\/ul>\n<p>\nA presentation will be available on Poxel&#8217;s website in the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.poxelpharma.com%2Fen_us%2Finvestors%2Fshareholder-information%2Fregulatory-documentation&amp;esheet=53366212&amp;newsitemid=20230322005650&amp;lan=en-US&amp;anchor=Investor+section&amp;index=2&amp;md5=c6cd3e4bfa0b3f64ed2ca7ca81ed6d05\" rel=\"nofollow noopener\" shape=\"rect\">Investor section<\/a>.\n<\/p>\n<p>\nTo register for the webcast in <b>French<\/b>:<br \/>\n<br \/><span class=\"bwuline\"><i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fapp.livestorm.co%2Fnewcap-1%2Fpresentation-des-resultats-annuels-2022-de-poxel%3Ftype%3Ddetailed&amp;esheet=53366212&amp;newsitemid=20230322005650&amp;lan=en-US&amp;anchor=https%3A%2F%2Fapp.livestorm.co%2Fnewcap-1%2Fpresentation-des-resultats-annuels-2022-de-poxel%3Ftype%3Ddetailed&amp;index=3&amp;md5=f065c9e5ab725c053e74f6f7b603f5ce\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/app.livestorm.co\/newcap-1\/presentation-des-resultats-annuels-2022-de-poxel?type=detailed<\/a><\/i><\/span>\n<\/p>\n<p>\nTo register for the webcast in <b>English:<br \/>\n<br \/><\/b><span class=\"bwuline\"><i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fapp.livestorm.co%2Fnewcap-1%2Fduplicata-presentation-of-poxel-and-39s-2022-full-year-results-copie%3Ftype%3Ddetailed&amp;esheet=53366212&amp;newsitemid=20230322005650&amp;lan=en-US&amp;anchor=https%3A%2F%2Fapp.livestorm.co%2Fnewcap-1%2Fduplicata-presentation-of-poxel-and-39s-2022-full-year-results-copie%3Ftype%3Ddetailed&amp;index=4&amp;md5=0762090ef1734f9a59b9ba4b31076311\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/app.livestorm.co\/newcap-1\/duplicata-presentation-of-poxel-and-39s-2022-full-year-results-copie?type=detailed<\/a><\/i><\/span>\n<\/p>\n<p>\n<b>About Poxel SA<\/b>\n<\/p>\n<p>\nPoxel is a <b>clinical stage biopharmaceutical company<\/b> developing <b>innovative treatments for chronic serious diseases with metabolic pathophysiology<\/b>, including <b>non-alcoholic steatohepatitis (NASH)<\/b> and rare disorders. For the treatment of NASH, <b>PXL065<\/b> (deuterium-stabilized <i>R<\/i>-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of <b>PXL770<\/b>, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). <b>TWYMEEG<sup>\u00ae<\/sup><\/b> (Imeglimin), Poxel\u2019s first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan, China, and eleven other Asian countries. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.\n<\/p>\n<p>\nFor more information, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxelpharma.com&amp;esheet=53366212&amp;newsitemid=20230322005650&amp;lan=en-US&amp;anchor=www.poxelpharma.com&amp;index=5&amp;md5=b7f2f8e227224de198e21b679907eaa5\" rel=\"nofollow noopener\" shape=\"rect\">www.poxelpharma.com<\/a>\n<\/p>\n<p>\nAll statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company\u2019s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould\u201d and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company\u2019s control that could cause the Company\u2019s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Contacts &#8211; Investor relations \/ Media<\/b><br \/>Aur\u00e9lie Bozza<br \/>\n<br \/>Investor Relations &amp; Communication Senior Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;o&#x3a;&#97;u&#x72;&#101;l&#x69;&#101;&#46;&#x62;&#x6f;z&#x7a;&#x61;&#64;&#x70;&#x6f;&#120;&#x65;&#x6c;&#112;h&#x61;&#114;m&#x61;&#46;c&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x61;&#x75;&#x72;&#101;&#108;ie&#x2e;&#x62;&#x6f;&#x7a;&#122;&#97;&#64;p&#x6f;&#x78;&#x65;&#108;&#112;&#104;ar&#x6d;&#x61;&#x2e;&#99;&#111;m<\/a><br \/>+33 6 99 81 08 36\n<\/p>\n<p>\nElizabeth Woo<br \/>\n<br \/>Senior Vice President, Investor Relations &amp; Communication<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#x3a;&#x65;&#108;&#x69;z&#97;&#x62;e&#116;&#x68;&#46;&#x77;o&#111;&#x40;p&#111;&#x78;&#101;&#x6c;&#x70;&#104;&#x61;r&#109;&#x61;&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x65;&#x6c;&#105;&#122;&#97;b&#x65;&#x74;&#x68;&#46;&#119;oo&#x40;&#x70;&#x6f;&#120;&#101;l&#x70;&#x68;&#x61;&#114;&#109;&#97;&#46;&#x63;&#x6f;&#x6d;<\/a>\n<\/p>\n<p>\nNewCap<br \/>\n<br \/>Emmanuel Huynh or Arthur Rouill\u00e9<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;&#x3a;p&#111;&#x78;e&#108;&#x40;&#x6e;e&#119;&#x63;a&#112;&#x2e;&#x65;u\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x6f;&#x78;&#101;&#x6c;&#x40;&#110;&#x65;&#x77;&#99;&#x61;&#x70;&#46;&#x65;&#x75;<\/a><br \/>+33 1 44 71 94 94\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>LYON, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: POXEL SA (Euronext: POXEL &#8211; FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced it will report its 2022 Full year results on March 23, 2023, before market opening. The management team will &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55100","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Poxel will Report its 2022 Full Year Results on March 23, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Poxel will Report its 2022 Full Year Results on March 23, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LYON, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: POXEL SA (Euronext: POXEL &#8211; FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced it will report its 2022 Full year results on March 23, 2023, before market opening. The management team will ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-22T18:05:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230322005650\/en\/729490\/21\/POXEL_LOGO_Q.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Poxel will Report its 2022 Full Year Results on March 23, 2023\",\"datePublished\":\"2023-03-22T18:05:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\\\/\"},\"wordCount\":468,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230322005650\\\/en\\\/729490\\\/21\\\/POXEL_LOGO_Q.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\\\/\",\"name\":\"Poxel will Report its 2022 Full Year Results on March 23, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230322005650\\\/en\\\/729490\\\/21\\\/POXEL_LOGO_Q.jpg\",\"datePublished\":\"2023-03-22T18:05:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230322005650\\\/en\\\/729490\\\/21\\\/POXEL_LOGO_Q.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230322005650\\\/en\\\/729490\\\/21\\\/POXEL_LOGO_Q.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Poxel will Report its 2022 Full Year Results on March 23, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Poxel will Report its 2022 Full Year Results on March 23, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/","og_locale":"en_US","og_type":"article","og_title":"Poxel will Report its 2022 Full Year Results on March 23, 2023 - Pharma Trend","og_description":"LYON, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: POXEL SA (Euronext: POXEL &#8211; FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced it will report its 2022 Full year results on March 23, 2023, before market opening. The management team will ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-22T18:05:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230322005650\/en\/729490\/21\/POXEL_LOGO_Q.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Poxel will Report its 2022 Full Year Results on March 23, 2023","datePublished":"2023-03-22T18:05:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/"},"wordCount":468,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230322005650\/en\/729490\/21\/POXEL_LOGO_Q.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/","url":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/","name":"Poxel will Report its 2022 Full Year Results on March 23, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230322005650\/en\/729490\/21\/POXEL_LOGO_Q.jpg","datePublished":"2023-03-22T18:05:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230322005650\/en\/729490\/21\/POXEL_LOGO_Q.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230322005650\/en\/729490\/21\/POXEL_LOGO_Q.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/poxel-will-report-its-2022-full-year-results-on-march-23-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Poxel will Report its 2022 Full Year Results on March 23, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55100"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55100\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}